Targeting novel peripheral mediators for the treatment of chronic pain

British Journal of Anaesthesia

Volumn 111, Issue 1, 2013, Pages 46-51

  Richards, N ^a   McMahon, S B ^a   Colvin, L ^a   Rowbotham, D J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

analgesia; chronic pain; nociception

Indexed keywords

CAPSAICIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLUCOCORTICOID; INTERLEUKIN 1BETA; LIDOCAINE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TANEZUMAB;

BLOOD BRAIN BARRIER; CHRONIC PAIN; DRUG EFFICACY; ELECTROPHYSIOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; INTERSTITIAL CYSTITIS; JOINT PROSTHESIS; META ANALYSIS (TOPIC); MUSCULOSKELETAL PAIN; NEUROPATHIC PAIN; NOCICEPTION; OSTEOARTHRITIS; PAIN ASSESSMENT; PAIN RECEPTOR; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGIONAL ANESTHESIA; REVIEW; RHEUMATOID ARTHRITIS; SENSITIZATION; SYMPTOM;

EID: 84880212754     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet216     Document Type: Review

References (55)

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333
2. http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-ABlueprint- for-Transforming-Prevention-Care-Education-Research. aspx
3. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain 2011; 152: 566-72
4. Hawker G, Wright J, Coyte P, et al. Health-related quality of life after knee replacement. J Bone Joint Surg Am 1998; 80: 163-73
5. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth 2002; 89: 409-23
6. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335: 2-13
7. Habib GS, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol 2010; 29: 347-56
8. Wood JN, Baker M. Voltage-gated sodium channels. Curr Opin Pharmacol 2001; 1: 17-21
9. Devor M, Govrin-Lippmann R, Angelides K.Na+channelimmunolocalization in peripheral mammalian axons and changes following nerve injury and neuromaformation. J Neurosci 1993; 13: 1976-92
10. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992; 48: 261-8
11. England S, Bevan S, Docherty RJ. PGE2 modulates the tetrodotoxinresistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol 1996; 495(Pt 2): 429-40
12. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73: 123-39
13. Attal N, Gaudé V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2007; 54: 564-74
14. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65: 39-44
15. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37: 246-53
16. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an openlabel, two-stage adaptive, randomized, controlled trial. Clin Drug Invest 2009; 29: 231-41
17. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151-8
18. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992; 51: 175-94
19. KoltzenburgM, Lundberg LE, Torebjork HE. Dynamic and staticcomponents of mechanical hyperalgesia in human hairy skin. Pain 1992; 51: 207-19
20. LaMotteRH, Shain CN,SimoneDA, Tsai EF. Neurogenichyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol 1991; 66: 190-211
21. SimoneDA, Ochoa J. Earlyand late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans. Pain 1991; 47: 285-94
22. Nolano M, Simone DA,Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81: 135-45
23. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. Br Med J 2004; 328: 991
24. McCormack PL. Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain. Drugs 2010; 70: 1831-42
25. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain 2006; 7: S3-12, doi:10.1016/j.jpain.2005.09.006 (2006)
26. Sugiura T, Tominaga M, Katsuya H, Mizumura K. Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 2002; 88: 544-8
27. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5
28. Ferreira SH. Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists. Br J Clin Pharmacol 1980; 10 (Suppl. 2): 237S-45S
29. Yaksh TL, Dirig DM, Malmberg AB. Mechanism of action of nonsteroidal anti-inflammatory drugs. Cancer Invest 1998; 16: 509-27
30. Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 2006; 23: 873-81
31. HeynemanCA, Lawless-Liday C,Wall GC. Oral versus topicalNSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60: 555-74
32. McNeill SC, Potts RO, Francoeur ML. Local enhanced topical delivery (LETD) of drugs: does it truly exist? Pharm Res 1992; 9: 1422-7
33. Pabreja K, Dua K, Padi SS. Evaluation of extemporaneously manufactured topical gels containing aceclofenac on inflammation and hyperalgesia in rats. Curr Drug Deliv 2010; 7: 324-8
34. Lin CR, Amaya F, Barrett L, et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharm Exp Ther 2006; 319: 1096-103, doi:10.1124/jpet.106.105569
35. Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol 2000; 130: 1418-24
36. EijkelkampN,Wang H, Garza-Carbajal A, et al. Lownociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. J Neurosci 2010; 30: 12806-15
37. Hong Y, Abbott FV. Behavioural effects of intraplantar injection of inflammatory mediators in the rat. Neuroscience 1994; 63: 827-36
38. Cunha TM, Talbot J, Pinto LG, et al. Caspase-1 is involved in the genesis of inflammatory hypernociception by contributing to peripheral IL-1beta maturation. Mol Pain 2010; 6: 63
39. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and metaanalysis. BMC Musculoskelet Disord 2004; 5: 28
40. Laas K, Peltomaa R, Puolakka K, Kautiainen H, Leirisalo-Repo M. Early improvement of health-related quality of life during treatmentwith etanercept and adalimumab in patientswith rheumatoid arthritis in routine practice. Clin Exp Rheumatol 2009; 27: 315-20
41. Genta MS, Kardes H, Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. Joint Bone Spine 2006; 73: 51-6
42. Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-52
43. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
44. Fioravanti A, Fabbroni M, Cerase A, GaleazziM. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009; 29: 961-5
45. Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2004; 4: 1333-44
46. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2004; 68: 1613-17
47. McMahon SB, Bennett DL, Priestley JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995; 1: 774-80
48. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-38
49. FDA report on Anti-NGF drugs. http://www.fda.gov/Advisory Committees/Calendar/ucm286556.htm
50. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. The New England Journal of Medicine 2010; 363: 1521-31
51. Katz N, Borenstein DG, Birbara C, et al. Efficacyand safety of tanezumab in the treatment of chronic low back pain. Pain 2011; 152: 2248-58
52. Te AE. A study to investigate tanezumab in patients with interstitial cystitis/painful bladder syndrome. Current Urology Reports 2011; 12: 245-6
53. McMahon SB, Bennett DHL, Bevan S. Inflammatory mediators and modulators of pain. In: McMahon SB, Koltzenburg M, eds. Wall and Melzack's Textbook of Pain, 5th Edn. London: Churchill Livingstone, 2006; 49-72
54. Dawes JM, Calvo M, Perkins JR, et al. CXCL5 mediates UVB irradiation-induced pain. Science Translational Medicine 2011; 3: 90ra60
55. Bishop T, Marchand F, Young AR, Lewin GR, McMahon SB. Ultraviolet-B-induced mechanical hyperalgesia: A role for peripheral sensitisation. Pain 2010; 150: 141-52